Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 75/100

Invivyd to Participate in Upcoming Investor Conferences

Key Takeaway: Invivyd, Inc. (Nasdaq: IVVD) has announced its participation in two prominent investor conferences scheduled for September 2023. The first event is the H.C. Wainwright 25th Annual Global Investment Conference, followed by the Morgan Stanley 21st Annual Global Healthcare Conference. Both events will feature fireside chats where the company will present its advancements in antibody-based therapies aimed at combatting viral infectious diseases. Live webcasts of the discussions will be available on the company’s investor website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is engaging in key investor conferences, showcasing company transparency.
  • Live webcasts aim to reach a wider audience, promoting accessibility.
  • The company has a robust pipeline with potential therapeutic advancements.

Full Press Release Details

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:
H.C. Wainwright 25th Annual Global Investment Conference
Fireside Chat Date: Monday, September 11, 2023
Fireside Chat Time: 3:00 PM ET
Location: New York, NY
Morgan Stanley 21st Annual Global Healthcare Conference
Fireside Chat Date: Wednesday, September 13, 2023
Fireside Chat Time: 12:55 PM ET
Location: New York, NY
Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 90 days following the events.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Gabriella Linville-Engler

Frequently Asked Questions

What is the mission of Invivyd, Inc.?

Invivyd aims to protect vulnerable populations from serious viral infectious diseases.

When is Invivyd presenting at the H.C. Wainwright conference?

Invivyd will present on September 11, 2023, at 3:00 PM ET.

Where can I watch Invivyd's fireside chats?

Live webcasts are available on Invivyd's investor website and archived for 90 days.

What innovative technologies does Invivyd use?

Invivyd employs evolutionary virology, predictive modeling, and antibody engineering.

What viral diseases is Invivyd targeting?

Their pipeline focuses on COVID-19, influenza, and other serious viral diseases.

Last updated: Sep 6, 2023